Blood test may someday predict which prostate cancer drugs will work

NCT ID NCT04662996

Completed Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study analyzed blood samples from 33 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers looked for tiny molecules called microRNAs that might predict whether a patient will resist chemotherapy or newer hormone drugs. The goal is to help doctors choose the most effective treatment from the start.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors choose the right treatment for each patient with metastatic castration-resistant prostate cancer, avoiding ineffective therapies.
What could go wrong: This was a small, observational study (33 people) that only looked for patterns in blood samples. It does not test a treatment, so it may not lead to any immediate change in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma Disease Resistance metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MICRORNAS PROSTATE CANCER RESISTANCE, DISEASE

Contacts and locations

Locations

University Hospital of Tours

Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.